Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls
Keywords:
pemphigus vulgaris, ELISA, cytokine, interleukin-4, interleukin-21Abstract
Background: Pemphigus is a rare group of autoimmune blistering diseases with unknown etiology and unclear pathogenesis. Pemphigus vulgaris (PV) is the most common subtype, and is characterized by ulcerations or flaccid blisters on mucous membranes and on the skin. It is accepted that cytokines have a critical role in the pathogenesis of PV, while their exact roles remain to be elucidated.
Objectives: This study assessed serum levels of interleukin (IL)-4 and IL-21 in different phases of the disease in comparison with healthy controls.
Methods: In a case-control cohort design, serum levels of IL-4 and IL-21 were determined by ELISA in three groups: patients with newly diagnosed PV, patients with chronic, inactive PV (PV in remission), and healthy controls.
Results: The study included 88 individuals (58 women and 30 men), including 26 with newly diagnosed PV, 33 with PV in remission, and 29 healthy controls. A significant difference was found among the groups for IL-21 (P = .044), but not for IL-4 (P = .374). Serum levels of IL-4 and IL-21 in newly diagnosed patients were significantly lower than in healthy controls (P = .005 for both), but these cytokine levels in patients with PV in remission were not different from those of controls (P = .343 and P = .221, respectively). Also, no differences in cytokine levels were detected between the newly diagnosed patients and patients with PV in remission. Regardless of disease phase, we detected significantly lower levels of IL-21 in patients than controls (P = .027), but no differences for IL-4 (P = .374).
Conclusions: IL-4 and IL-21 are involved in PV pathogenesis and disease severity. More studies are required to clarify the role of IL-4 and IL-21 in immunopathogenesis and immune response during PV.
References
Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22(11):699-704. DOI: 10.1111/exd.12229. PMID: 24433179.
Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimm Rev. 2020:102661. DOI: 10.1016/j.autrev.2020.102661. PMID: 32942041.
Tavakolpour S, Mahmoudi H, Mirzazadeh A, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine. 2020;129:155026. DOI: 10.1016/j.cyto.2020.155026. PMID: 32058276.
Mahmoudi H, Ebrahimi E, Daneshpazhooh M, et al. Single‐nucleotide polymorphisms associated with pemphigus vulgaris: potent markers for better treatment and personalized medicine. Int J Immunogenet. 2020;47(1):41-49. DOI: 10.1111/iji.12451.PMID: 31342641.
Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016;77:1891-95. DOI: 10.1016/j.cyto.2015.09.017. PMID: 26440137.
Cho MJ, Ellebrecht CT, Payne AS. The dual nature of interleukin-10 in pemphigus vulgaris. Cytokine. 2015;73(2):335-341. DOI: 10.1016/j.cyto.2014.11.002. PMID: 25464924.
Tavakolpour S. Interleukin 21 as a new possible player in pemphigus: Is it a suitable target? Int Immunopharmacol. 2016;34:139-145. DOI: 10.1016/j.intimp.2016.02.020. PMID: 26945832.
Tavakolpour S, Kheiry F, Mirsafaei HS, Akhlaghdoust M. The possible role of interleukin-35 and its therapeutic potential in pemphigus. Int Immunopharmacol. 2017;42:11-7. DOI: 10.1016/j.intimp.2016.11.005. PMID: 27855302.
Takahashi H, Kouno M, Nagao K, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest. 2011;121(9):3677-3688. DOI: 10.1172/JCI57379. PMID: 21821914.
Veldman CM, Gebhard KL, Uter W, et al. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol. 2004;172(6):3883. DOI: 10.4049/jimmunol.172.6.3883. PMID: 15004196.
Hennerici T, Pollmann R, Schmidt T, et al. Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus. PloS One. 2016;11(2):e0148919. DOI: 10.1371/journal.pone.0148919. PMID: 26872212.
Zhu H, Chen Y, Zhou Y, Wang Y, Zheng J, Pan M. Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris. J Clin Immunol. 2012;32(1):114-123. DOI: 10.1007/s10875-011-9597-4. PMID: 22009001.
Xu RC, Zhu HQ, Li WP, Zhao XQ, Yuan HJ, Zheng J, et al. The imbalance of Th17 and regulatory T cells in pemphigus patients. Eur J Dermatol. 2013;23(6):795-802. DOI: 10.1684/ejd.2013.2177. PMID: 24192290.
Kim AR, Han D, Choi JY, Seok J, Kim S-E, Seo S-H, et al. Targeting ICOS expressed on CXCR5+ PD-1+ T helper cells suppresses the progression of pemphigus vulgaris. J Allergy Clin Immunol. 2020;146(5):1070-1079.e8. DOI: 10.1016/j.jaci.2020.03.036. PMID: 32311391.
Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016;77:189-95. DOI: 10.1016/j.cyto.2015.09.017. PMID: 26440137.
Murrell DF, Dick S, Ahmed A, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046. DOI: 10.1016/j.jaad.2008.01.012. PMID: 18339444.
Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest. 2009;38(6):498-509. DOI: 10.1080/08820130902943097. PMID: 19811408.
El-Darouti MA, Hegazy RA, Abdel Hay RM, et al. Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial. Arch Dermatol Res. 2015;307(4):299-307. DOI: 10.1007/s00403-014-1522-2. PMID: 25450635.
Lee SH, Hong WJ, Kim S-C. Analysis of serum cytokine profile in pemphigus. Ann Dermatol. 2017;29(4):438-445. DOI: 10.5021/ad.2017.29.4.438. PMID: 28761292.
Timoteo RP, da Silva MV, Miguel CB, et al. Th1/Th17-related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris. Mediators Inflamm. 2017;2017:7151285. DOI: 10.1155/2017/7151285. PMID: 28321152.
Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016;29(5):299. DOI: 10.1111/dth.12327. PMID: 26800435.
Yuan H, Zhou S, Liu Z, et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis. J Invest Dermatol. 2017;137(11):2362-2370. DOI: 10.1016/j.jid.2017.05.032. PMID: 28647348.
Tavakolpour S. Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges. Immunol Letters. 2017;190:130-138. DOI: 10.1016/j.imlet.2017.08.002. PMID: 28797806.
Tavakolpour S, Mahmoudi H, Karami F, et al. Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: potentials roles of CTLA4 and FCGR3A genes expressio in outcomes of rituximab therapy. Dermatol Ther. 2020;33(6):e14380. DOI: 10.111/dth.14380. PMID: 33090639.
Balighi K, Daneshpazhooh M, Akbari Z, Tavakolpour S, Azimi P, Azizpour A. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. J Dermatolog Treat. 2018:1-4. DOI: 10.1080/09546634.2018.1509049. PMID: 30081690.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
